Green Cross US Subsidiary Curevo Raises $26 Million in Series A1 Funding

Curevo CI (Photo by Curevo)

[Asia Economy Reporter Chunhee Lee] GC Green Cross announced on the 17th that its US subsidiary Curevo successfully raised an additional $26 million (approximately 34.7 billion KRW) in Series A1 funding, following the $60 million Series A funding conducted in February.

This funding round included joint investors Janus Henderson Investors, RA Capital Management, Adjuvant Capital, and GC Green Cross.

Based on the raised funds, Curevo is currently conducting a Phase 2b clinical trial of the shingles vaccine ‘CRV-101’. The registration of 678 patients was completed within six months of the trial's commencement, and interim results are expected to be announced in the first half of next year.

CRV-101 is a subunit vaccine designed to have similar efficacy to existing shingles vaccines while reducing the burden of side effects. In Phase 1 clinical trials, there were no Grade 3 injection site reactions, and Grade 3 systemic adverse events occurred at a low rate (1.3%). On the other hand, it showed strong immunogenicity based on humoral and cellular response measurements.

George Simeon, CEO of Curevo, said, “The additional A1 funding raised ahead of the Phase 2b interim results announcement demonstrates investors' confidence in CRV-101,” adding, “With consecutive funding rounds, we expect to accelerate clinical research.” Huh Euncheol, CEO of GC Green Cross, also stated, “We are pleased to develop a shingles prevention vaccine through Curevo,” and “We look forward to the interim results of CRV-101 to be announced early next year.”

This content was produced with the assistance of AI translation services.